LAUSANNE, Switzerland, April 1, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will present a company overview at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, 2025, at 8:00 a.m. ET. A live webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics' website, ir.adctherapeutics.com. A replay of the webcast will be available for approximately 30 da ...

However, several companies offer higher-yielding payouts for those seeking a bit more dividend income. Here are four top dividend stocks yielding around 4% these days that you can confidently buy for dividend income this April. Agree Realty Agree Realty (ADC 1.16%) has a 4% dividend yield. The real estate investment trust (REIT) focuses solely on owning single-tenant net lease and ground lease retail properties. Those lease structures provide very stable cash flow. Meanwhile, the REIT pays very close attent ...

Agree Realty Corporation is a publicly traded real estate investment trust that is RETHINKING RETAIL through the acquisition and development of properties net leased to industry-leading, omni-channel retail tenants. As of December 31, 2024, the Company owned and operated a portfolio of 2,370 properties, located in all 50 states and containing approximately 48.8 million square feet of gross leasable area. The Company's common stock is listed on the New York Stock Exchange under the symbol "ADC". Forward-Look ...

Core Viewpoint - Agree Realty (NYSE: ADC) has experienced a nearly 9% increase year-to-date on a total return basis, contrasting with the broader downturn affecting REITs due to a significantly narrower outlook for Federal Reserve rate cuts in 2025 and rising long-term US yields [1] Group 1 - The equity market serves as a powerful mechanism where daily price fluctuations can lead to substantial wealth creation or destruction over the long term [1] - Pacifica Yield focuses on long-term wealth creation by targeting undervalued yet high-growth companies, high-dividend stocks, REITs, and green energy firms [1]

Core Insights - ADC Therapeutics reported significant progress in clinical trials for ZYNLONTA, with a 94% overall response rate (ORR) and a 72% complete response (CR) rate in the LOTIS-7 Phase 1b trial [1][5] - The company completed enrollment in the LOTIS-5 Phase 3 trial, with data updates expected in late 2025 [1][5] - Financial results for Q4 and full year 2024 showed a net product revenue of $16.4 million for Q4 and $69.3 million for the full year, indicating a slight increase compared to 2023 [8][22] Operational Updates - The LOTIS-7 trial demonstrated promising initial data, with 94% ORR and 72% CR in patients with relapsed or refractory non-Hodgkin lymphoma [5] - Enrollment for the LOTIS-5 trial was completed in December 2024, with data updates anticipated once progression-free survival (PFS) events are reached [5] - The company is also advancing its early research solid tumor program to the IND-enabling stage [2] Financial Performance - Q4 2024 net product revenues were $16.4 million, compared to $16.6 million in Q4 2023, while full-year revenues increased from $69.1 million in 2023 to $69.3 million in 2024 [8][22] - Research and development expenses decreased to $27.1 million for Q4 2024 from $30.3 million in Q4 2023, and full-year expenses dropped from $127.1 million to $109.6 million [8][22] - The net loss for Q4 2024 was $30.7 million, a significant reduction from $85.0 million in Q4 2023, and the full-year net loss decreased from $240.1 million to $157.8 million [8][22] Cash Position - As of December 31, 2024, the company had $250.9 million in cash and cash equivalents, down from $278.6 million in 2023, providing a runway expected to fund operations into the second half of 2026 [1][8]

Group 1 - ADC Therapeutics is positioned in the large B-cell lymphoma market with its antibody-drug conjugate [1] - The company has previously shown optimism in its market positioning, leading to a rally in stock price [1] - The author has a background in biochemistry and experience in analyzing clinical trials and biotech companies, emphasizing the importance of understanding the science behind investments [1]

Core Viewpoint - Innovent Biologics has initiated the first participant dosing in a Phase 3 clinical trial (HeriCare-Ovarian01) for IBI354, targeting platinum-resistant ovarian cancer with HER2 expression, addressing an urgent medical need in this patient population [1][2][8]. Company Overview - Innovent Biologics is a biopharmaceutical company focused on developing high-quality medicines for various diseases, including oncology, cardiovascular, and autoimmune conditions [1][13]. - The company has launched 15 products and has multiple assets in various stages of clinical trials, indicating a robust pipeline and commitment to innovation [13]. Clinical Trial Details - The HeriCare-Ovarian01 trial is the first Phase 3 study in China for platinum-resistant ovarian cancer with HER2 expression, evaluating the safety and efficacy of IBI354 against standard chemotherapy [2][5]. - The primary endpoints of the trial include progression-free survival (PFS) and overall survival (OS) [2]. Previous Study Results - In a prior Phase 1/2 study, IBI354 demonstrated a 40.2% overall objective response rate (ORR) and an 81.6% disease control rate (DCR) among participants with platinum-resistant ovarian cancer [7]. - Notably, the ORR reached 52.5% and DCR 90.0% in patients treated with a 12 mg/kg dose [7]. Safety Profile - IBI354 has shown an excellent safety profile, with a low incidence of treatment-related adverse events (TRAEs) and no dose-limiting toxicities reported up to an 18 mg/kg dose [7][4]. - The most common TRAEs included nausea and decreased white blood cell count, with a very low incidence of interstitial lung disease [7]. HER2 Targeting - Approximately 38% of ovarian cancer patients express HER2, and there are currently no approved anti-HER2 treatments for this condition in China, highlighting the potential market opportunity for IBI354 [9][10]. - IBI354 is an innovative HER2-targeted antibody-drug conjugate developed using a proprietary platform, showcasing promising safety and efficacy signals [10][11]. Future Development - Innovent plans to expand the development of IBI354 to multiple solid tumor indications beyond ovarian cancer, indicating a strategic focus on broadening its therapeutic applications [12].

Group 1 - Agree Realty (NYSE: ADC) is highlighted as a strong investment within the REIT sector, particularly due to purchases made in the first half of 2024 [1] - The author emphasizes the importance of dividend investing as a pathway to financial freedom, leveraging experience in M&A and business valuation [2] - The focus of the author's investment strategy includes sectors such as tech, real estate, software, finance, and consumer staples, which form the core of the portfolio [2] Group 2 - The article expresses a beneficial long position in ADC shares, indicating confidence in the investment [3] - There is a clear intention to share insights and experiences related to dividend investing to help others in their financial journeys [2] - The content does not provide specific investment recommendations or advice, maintaining a neutral stance on investment suitability [4][5]

Core Insights - ADC Therapeutics SA is a global leader in antibody drug conjugates (ADCs) and will host a conference call on March 27, 2025, to report financial results for Q4 and the year ended December 31, 2024 [1][2] - The company is advancing its proprietary ADC technology to improve treatment for patients with hematologic malignancies and solid tumors [3] - ADC Therapeutics' ZYNLONTA (loncastuximab tesirine-lpyl) has received accelerated approval from the FDA and conditional approval from the European Commission for treating relapsed or refractory diffuse large B-cell lymphoma [4] Company Overview - ADC Therapeutics is based in Lausanne, Switzerland, with operations in London and New Jersey [5] - The company is focused on developing multiple ADCs that are currently in clinical and preclinical stages [4] Upcoming Events - The conference call will provide operational updates and is accessible via a live webcast on the company's investor relations website [2]

Group 1 - The value factor in investing becomes less attractive when growth stocks outperform for an extended period, as seen with companies like NVIDIA and Tesla [1] - Roberts Berzins has over a decade of experience in financial management, focusing on corporate financial strategies and large-scale financings [1] - Berzins has contributed to the institutionalization of the REIT framework in Latvia to enhance liquidity in pan-Baltic capital markets [1] Group 2 - Berzins has developed national SOE financing guidelines and frameworks to channel private capital into affordable housing [1] - He holds a CFA Charter and an ESG investing certificate, and has experience with the Chicago Board of Trade [1] - Berzins is actively involved in thought-leadership activities to support the development of pan-Baltic capital markets [1]